Viral diseases, treatment Inhibitors

In 2001, tenofovir disoproxil fumarate 61, a prodrug of tenofovir was approved for treatment of HIV, subsequently being preregistered in the USA for treatment of hepatitis B. Emtricitabine 62, a reverse transcriptase inhibitor, was approved in 2003 for HIV. What is of import is that these compounds are now part of fixed dose combination therapies for treatment of HIV, either two drug (tenofovir disoproxil fumarate/emtricitabine) or three drug Atripla (tenofovir disoproxil fumarate/emtricitabine/efavirenz) formulations. Thus, even 50 + years after Bergmann s discovery of bioactive arabinose nucleosides, small molecules synthesised as result of his discoveries are still in clinical use and others are in clinical trials for treatment of viral diseases. 

As a concluding statement, the fact that a treatment works for some, at least some of the time, is an indication that it should be perfected rather than rejected. Nor is it always necessary to understand how a treatment works, for what we are most interested in are results. For example, we may never know exactly how antibiotics work, other than that they are enzyme inhibitors. This, in spite of all the biochemical formnlas and equations, and the lengthy, technical, and encyclopedic treatises on the subject. For every answered question always leads to further questions. Ditto for the immunizations against various viral diseases, such as polio and smallpox — though we seem almost at a point that for some diseases the only new cases seem to be from the vaccination itself. Nevertheless, we are most grateful that antibiotics and immunizations most often do work, and we ll accept the same for any treatment of cancer. 

Major Appiications Fuel cell power generation system, liquid crystal displays, solor cells, sensors, thermochromic materials,coloring wood,n detergents, assessment of tobacco smoke, cosmetics,14 detect bacterial infections,i multidrug resistance inhibitors, treatment of bums, endodontic, diabetes, obesity, 5 cancer,2o age-related macular degeneration, viral diseases Safety/Toxicity Acute toxicity, combustion toxicity, 4 cytotoxicity, genotoxicity, mutagenicity, nephrotoxicity, phototoxicity, soil toxicity ... 

Neuraminidase is an essential viral glycoprotein for virus replication and release. The neuraminidase inhibitors zanamivir and oseltamivir have recently been approved for the treatment of acute uncomplicated influenza infection. When a 5-day course of therapy is initiated within 36-48 hours after the onset of symptoms, use of either agent shortens the severity and duration of illness and may decrease the incidence of respiratory complications in children and adults. Unlike amantadine and rimantidine, zanamivir and oseltamivir have activity against both influenza A and influenza B. Zanamivir is administered via oral inhaler. The compound displays poor oral bioavailability, limited plasma protein binding, rapid renal clearance, and absence of significant metabolism. Nasal and throat discomfort may occur—as well as bronchospasm in patients with reactive airway disease. 

The effectiveness of HIV-1 protease inhibitors in reducing disease progression and mortality and the associated increase in CD4 cells along with the viral burden established protease inhibitors plus dual nucleosides as the paradigm for HIV-1 treatment. Several key questions remain What is the optimal time to initiate therapy What is the optimal treatment regimen What is the most effective treatment after initial medications have failed ... 

Tricyclic thiopyran-2-one derivatives are useful in the development of therapies for the treatment of viral infections and diseases including AIDS <1996USP5504104>. The thiocoumarin 583 has been identified as a weak inhibitor of inducible nitric oxide synthase <2005BMC2723> and the (l,3,4-thiadiazol-5-yl)thiocoumarin 584 is active against monoamine oxidase B in rat brains <1994EPP594036>. 

The enzymes that manipulate nucleotides, nucleic acids, etc. are the points of therapeutic intervention for a number of diseases involving cell replication disorders such as cancers and viral infections. For instance, AZT 10.10, an inhibitor of the enzyme reverse transcriptase, is an anti-viral drug currently used in the treatment of AIDS. 

The AIDS virus is a retrovirus that is, it stores its genetic information in the form of RNA. On infection it injects its RNA into the target cell and uses an enzyme called reverse transcriptase to synthesize DNA that is complementary to this RNA template. AZT is accepted by reverse transcriptase as a building block for this synthesis and slows or prevents the conversion of the viral RNA information into DNA. By disrupting this process, AZT slows the replication of the virus in the cell. The nucleoside analog 2, 3 -dideoxycytidine (DDC) works in a similar manner. Current treatments, which use a cocktail of two nucleoside analogs and a protease inhibitor, seem to at least slow the progress of the disease. 

---